LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "plus adt" as a keyword



Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis

Sign Up to like & get
recommendations! Published in 2017 at "European Journal of Cancer"

DOI: 10.1016/j.ejca.2017.07.003

Abstract: Background There is a need to synthesise the results of numerous randomised controlled trials evaluating the addition of therapies to androgen deprivation therapy (ADT) for men with metastatic hormone-sensitive prostate cancer (mHSPC). This systematic review… read more here.

Keywords: plus adt; aap plus; meta; cancer ... See more keywords

Abstract CT190: Latin American patient subgroup analysis of the phase 3 TITAN study: Apalutamide plus ADT in metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Sign Up to like & get
recommendations! Published in 2021 at "Clinical Trials"

DOI: 10.1158/1538-7445.am2021-ct190

Abstract: Background: Apalutamide (APA) is an approved treatment in various countries of Latin America to treat patients with metastatic hormone-sensitive prostate cancer (mCSPC) patients based on the TITAN study interim analysis, which demonstrated an improved overall… read more here.

Keywords: titan study; cancer; plus adt; apa ... See more keywords

Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer

Sign Up to like & get
recommendations! Published in 2022 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.22.00193

Abstract: Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet… read more here.

Keywords: end; placebo plus; plus adt; enzalutamide plus ... See more keywords

A network meta-analysis of the safety of systemic treatments in patients with metastatic hormone-sensitive prostate cancer

Sign Up to like & get
recommendations! Published in 2025 at "Frontiers in Oncology"

DOI: 10.3389/fonc.2025.1468928

Abstract: Background The last decade saw the emergence of several new systemic therapies for metastatic hormone-sensitive prostate cancer (mHSPC). While these treatments demonstrated similar efficacy in indirect comparisons, comparisons of safety outcomes are needed to help… read more here.

Keywords: systemic treatments; safety; network; aap plus ... See more keywords